References
- C Holden. (2000). Global survey examines impact of depression. Science 288 (5463):39–40.
- F Kerrigan. (1998). Antidepressant patents: 1995–1997. Exp Opin Ther Pat 8 (4):439–460.
- I Hindmarch. (2001). Expanding the horizons of depression: Beyond the monamine hypothesis. Psychopharmacol Clin Exp 16:203–218.
- FT Crews, and CB Smith. (1978). Presynaptic alpha-receptor subsensitivity after long-term antidepressant treatment. Science 202 (4365):322–324.
- C Spyraki, and HC Fibiger. (1980). Functional evidence for subsensitivity of noradrenergic alpha -2-receptors after chronic desipramine treatment. Life Sci 27 (20):1863–1867.
- JJ Rutter, C Gundlah, and SB Auerbach. (1995). Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse 20 (3):225–233.
- M Briley, and C Moret. (1993). Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 16 (5):387–400.
- WZ Potter, MV Rudorfer, and H Manji. (1991). The pharmacologic treatment of depression. N Eng J Med 325 (9):633–642.
- HM Van Praag, GM Asnis, and RS Kahn. (1990). Monoamines and abnormal behaviour: A multi-aminergic perspective. Brit J Psychiatry 157 (5):723–734.
- JL Cummings. (1993). The neuroanatomy of depression. J Clin Psychiatry 54 (11):14–20.
- JP Kelly, AS Wrynn, and BE Leonard. (1997). The olfactory bulbectomized rat as a model of depression: An update. Pharmacol Ther 74 (3):299–316.
- F Artigas. (1995). Selective Serotonin Noradrenaline. Reuptake Inhibitors. CNS Drugs 4 (2):79–89.
- PV Tran, FP Bymaster, RK McNamara, and WZ Potter. (2003). Dual Monoamine modulation for improved treatment of major depression. J Clin Psychopharmacol 23 (1):78–86.
- KJ Carrie, JE Brian, BN Anne, and ES Harlan. (2006). Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 51 (8):1172–1180.
- FP Bymaster, RK McNamara, and PV Tran. (2003). New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin Investig Drugs 12 (4):531–543.
- JA Ignacio, A Jesus, MA Jose, ID Ana, I Laura, B Ilse, and AM Anton. (2006). Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HTUptake inhibiting and 2-adrenoceptor antagonistic activities: A novel series of potential antidepressants. Bioorg Med Chem 14 (13):4361–4372.
- JA Ignacio, A Jesus, MA Jose, MA Rosa, MC Jose, AD Lucas, J Fernandez, S Martınez, N Carmen, J Pastor, HB Margot, L Heylen, and AA Megens. (2003). Synthesis of 3α, 4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HTUptake inhibiting and 2-adrenoceptor antagonistic activities: A novel series of potential antidepressants. Bioorg Med Chem Lett 13 (16):2719–2725.
- T Kumiko, JK Todd, AH Nicholas, PR Vincent, GS Patrick, JK Daniel, LN David, W Bradley, JA Laura, S Janice, GT Penny, and TW David. (2003). Advances toward new antidepressants beyond SSRIs: 1-Aryloxy-3-piperidinylpropan-2-ols with Dual 5-HT1A receptor antagonism/SSRI activities. Part 3. Bioorg Med Chem Lett 13 (11):1903–1905.
- Z Dahui, LH Boyd, S Uresh, HA Terrance, AH Geoffrey, S Rosemary, ES Lee, LS Deborah, MS Kelly, and EM Richard. (2006). Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity. Bioorg Med Chem Lett 16 (5):1338–1341.
- JI Andres, J Alcazar, JM Alonso, RM Alvarez, MH Bakker, and I Biesmans. (2005). Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with (2-adrenoceptor blocking activity. J Med Chem 48 (6):2054–2071.
- JR Boot, SL Boulet, BP Clark, MJL Cases-Thomas, KD Delhaye, J Fairhurst, J Findlay, PT Gallagher, J Gilmore, JR Harris, JJ Masters, SN Mitchell, M Naik, RG Simmonds, SM Smith, SJ Richards, GH Timms, MA Whatton, CN Wolfe, and VA Wood. (2006). N-Alkyl-N-arylmethylpiperidin-4-amines: Novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett 16 (10):2714–2718.
- A Verloop, and HW Tipker. Development and application of new steric substituent parameters in drug design. In: EJ Ariens. editor Drug design. New York: Academic Press; (1976). p 165–207.
- A Verloop, and J Tipker. (1976). Use of linear free energy related and other parameters in the study of fungicidal selectivity. Pesticide Sci 7 (4):379–390.
- A Verloop, and J Tipker. A comparative study of new parameters in drug design. In: JA Keverling. editor. Biological activity and chemical structure. Amsterdam: Elsevier; (1977). p 63–81.